Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Sep;58(9):2862–2868. doi: 10.1128/iai.58.9.2862-2868.1990

Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides.

P J Baker 1, C E Taylor 1, P W Stashak 1, M B Fauntleroy 1, K Hasløv 1, N Qureshi 1, K Takayama 1
PMCID: PMC313579  PMID: 2143752

Abstract

Antibody responses of mice immunized with type III pneumococcal polysaccharide were examined with and without treatment with nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides (Rs-LPS). The results obtained were similar to those described previously for mice treated with monophosphoryl lipid A (MPL) except that lower amounts of Rs-LPS were needed. Both were without effect when given at the time of immunization with type III pneumococcal polysaccharide but elicited significant enhancement when given 2 to 3 days later. Such enhancement was T cell dependent and not due to polyclonal activation of immunoglobulin M synthesis by B cells. Treatment with either Rs-LPS or MPL abolished the expression but not induction of low-dose paralysis, a form of immunological unresponsiveness known to be mediated by suppressor T cells (Ts). The in vitro treatment of cell suspensions containing Ts with extremely small amounts of Rs-LPS or MPI completely eliminated the capacity of such cells to transfer suppression to other mice. These findings indicate that the immunomodulatory effects of both MPL and Rs-LPS are mainly the result of eliminating the inhibitors effects of Ts; this permits the positive effects of amplifier T cells to be more fully expressed, thereby resulting in an increased antibody response. The significance of these and other findings to the use of Rs-LPS as a pharmacotherapeutic agent for gram-negative bacterial sepsis is discussed.

Full text

PDF
2862

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker P. H., Stashak P. W. Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at ehe cellular level. J Immunol. 1969 Dec;103(6):1342–1348. [PubMed] [Google Scholar]
  2. Baker P. J., Amsbaugh D. F., Stashak P. W., Caldes G., Prescott B. Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide. J Immunol. 1982 Mar;128(3):1059–1062. [PubMed] [Google Scholar]
  3. Baker P. J., Amsbaugh D. F., Stashak P. W., Caldes G., Prescott B. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev Infect Dis. 1981 Mar-Apr;3(2):332–341. doi: 10.1093/clinids/3.2.332. [DOI] [PubMed] [Google Scholar]
  4. Baker P. J., Fauntleroy M. B., Prescott B. Examination of the differential characteristics of amplifier and contrasuppressor T cells. Immunobiology. 1988 Sep;177(4-5):438–448. doi: 10.1016/S0171-2985(88)80010-X. [DOI] [PubMed] [Google Scholar]
  5. Baker P. J., Haslov K. R., Fauntleroy M. B., Stashak P. W., Myers K., Ulrich J. T. Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect Immun. 1990 Mar;58(3):726–731. doi: 10.1128/iai.58.3.726-731.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baker P. J., Hiernaux J. R., Fauntleroy M. B., Prescott B., Cantrell J. L., Rudbach J. A. Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect Immun. 1988 May;56(5):1076–1083. doi: 10.1128/iai.56.5.1076-1083.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baker P. J., Hiernaux J. R., Fauntleroy M. B., Stashak P. W., Prescott B., Cantrell J. L., Rudbach J. A. Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun. 1988 Dec;56(12):3064–3066. doi: 10.1128/iai.56.12.3064-3066.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Baker P. J., Prescott B., Stashak P. W., Amsbaugh D. F. Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells. J Immunol. 1971 Sep;107(3):719–724. [PubMed] [Google Scholar]
  9. Baker P. J., Reed N. D., Stashak P. W., Amsbaugh D. F., Prescott B. Regulation of the antibody response to type 3 pneumococcal polysaccharide. I. Nature of regulatory cells. J Exp Med. 1973 Jun 1;137(6):1431–1441. doi: 10.1084/jem.137.6.1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Baker P. J., Stashak P. W., Amsbaugh D. F., Prescott B. Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response. Immunology. 1971 Apr;20(4):469–480. [PMC free article] [PubMed] [Google Scholar]
  11. Baker P. J., Stashak P. W., Amsbaugh D. F., Prescott B. Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. II. Studies on the relative rate of antibody synthesis and release by antibody-producing cells. Immunology. 1971 Apr;20(4):481–492. [PMC free article] [PubMed] [Google Scholar]
  12. Baker P. J., Stashak P. W., Amsbaugh D. F., Prescott B. Regulation of the antibody response to type 3 pneumococcal polysaccharide. II. Mode of action of thymic-derived suppressor cells. J Immunol. 1974 Jan;112(1):404–409. [PubMed] [Google Scholar]
  13. Baker P. J., Stashak P. W., Prescott B. Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells. Appl Microbiol. 1969 Mar;17(3):422–426. doi: 10.1128/am.17.3.422-426.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Baker P. J., Taylor C., Fauntleroy M. B., Stashak P. W., Prescott B. The role of antigen in the activation of regulatory T cells by immune B cells. Cell Immunol. 1985 Dec;96(2):376–385. doi: 10.1016/0008-8749(85)90368-5. [DOI] [PubMed] [Google Scholar]
  15. Bauss F., Dröge W., Männel D. N. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun. 1987 Jul;55(7):1622–1625. doi: 10.1128/iai.55.7.1622-1625.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  17. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  18. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  19. Galanos C., Lüderitz O., Westphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem. 1969 Jun;9(2):245–249. doi: 10.1111/j.1432-1033.1969.tb00601.x. [DOI] [PubMed] [Google Scholar]
  20. Gottlieb C. F. Application of transformations to normalize the distribution of plaque-forming cells. J Immunol. 1974 Jul;113(1):51–57. [PubMed] [Google Scholar]
  21. Gronowicz E., Coutinho A., Melchers F. A plaque assay for all cells secreting Ig of a given type or class. Eur J Immunol. 1976 Aug;6(8):588–590. doi: 10.1002/eji.1830060812. [DOI] [PubMed] [Google Scholar]
  22. HUMPHREY J. H., PARROTT D. M., EAST J. STUDIES ON GLOBULIN AND ANTIBODY PRODUCTION IN MICE THYMECTOMIZED AT BIRTH. Immunology. 1964 Jul;7:419–439. [PMC free article] [PubMed] [Google Scholar]
  23. Jones J. M., Amsbaugh D. F., Stashak P. W., Prescott B., Baker P. J., Alling D. W. Kinetics of the antibody response to type III pneumococcal polysaccharide. I. Evidence that suppressor cells function by inhibiting the recruitment and proliferation of antibody-producing cells. J Immunol. 1976 Mar;116(3):647–656. [PubMed] [Google Scholar]
  24. Lehmann V., Freudenberg M. A., Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med. 1987 Mar 1;165(3):657–663. doi: 10.1084/jem.165.3.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Morrison D. C., Ryan J. L. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417–432. doi: 10.1146/annurev.me.38.020187.002221. [DOI] [PubMed] [Google Scholar]
  26. Qureshi N., Honovich J. P., Hara H., Cotter R. J., Takayama K. Location of fatty acids in lipid A obtained from lipopolysaccharide of Rhodopseudomonas sphaeroides ATCC 17023. J Biol Chem. 1988 Apr 25;263(12):5502–5504. [PubMed] [Google Scholar]
  27. Qureshi N., Takayama K., Heller D., Fenselau C. Position of ester groups in the lipid A backbone of lipopolysaccharides obtained from Salmonella typhimurium. J Biol Chem. 1983 Nov 10;258(21):12947–12951. [PubMed] [Google Scholar]
  28. Qureshi N., Takayama K., Mascagni P., Honovich J., Wong R., Cotter R. J. Complete structural determination of lipopolysaccharide obtained from deep rough mutant of Escherichia coli. Purification by high performance liquid chromatography and direct analysis by plasma desorption mass spectrometry. J Biol Chem. 1988 Aug 25;263(24):11971–11976. [PubMed] [Google Scholar]
  29. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 1982 Oct 10;257(19):11808–11815. [PubMed] [Google Scholar]
  30. Remick D. G., Larrick J., Kunkel S. L. Tumor necrosis factor-induced alterations in circulating leukocyte populations. Biochem Biophys Res Commun. 1986 Dec 15;141(2):818–824. doi: 10.1016/s0006-291x(86)80246-7. [DOI] [PubMed] [Google Scholar]
  31. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod. 1984;3(1):1–9. [PubMed] [Google Scholar]
  32. Ribi E., Cantrell J. L., Takayama K., Qureshi N., Peterson J., Ribi H. O. Lipid A and immunotherapy. Rev Infect Dis. 1984 Jul-Aug;6(4):567–572. doi: 10.1093/clinids/6.4.567. [DOI] [PubMed] [Google Scholar]
  33. Salimath P. V., Tharanathan R. N., Weckesser J., Mayer H. The structure of the polysaccharide moiety of Rhodopseudomonas sphaeroides ATCC 17023 lipopolysaccharide. Eur J Biochem. 1984 Oct 15;144(2):227–232. doi: 10.1111/j.1432-1033.1984.tb08454.x. [DOI] [PubMed] [Google Scholar]
  34. Strittmatter W., Weckesser J., Salimath P. V., Galanos C. Nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides ATCC 17023. J Bacteriol. 1983 Jul;155(1):153–158. doi: 10.1128/jb.155.1.153-158.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Takayama K., Qureshi N., Beutler B., Kirkland T. N. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immun. 1989 Apr;57(4):1336–1338. doi: 10.1128/iai.57.4.1336-1338.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Takayama K., Qureshi N., Mascagni P. Complete structure of lipid A obtained from the lipopolysaccharides of the heptoseless mutant of Salmonella typhimurium. J Biol Chem. 1983 Nov 10;258(21):12801–12803. [PubMed] [Google Scholar]
  37. Taylor C. E., Stashak P. W., Caldes G., Prescott B., Chused T. E., Brooks A., Baker P. J. Activation of antigen-specific suppressor T cells by B cells from mice immunized with type III pneumococcal polysaccharide. J Exp Med. 1983 Sep 1;158(3):703–717. doi: 10.1084/jem.158.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES